An Insight about Quinolone Resistance

Abstract

Quinolone resistance in bacteria represents a significant global health threat, compromising the efficacy of crucial antibiotics used to treat a wide range of infections. This resistance arises primarily through mutations in genes encoding topoisomerases, the enzymes targeted by quinolones. These mutations, often located in the quinolone resistance-determining regions (QRDRs) of gyrA, gyrB, parC, and parE, reduce drug binding affinity and consequently inhibit enzymatic inhibition. However, resistance is a multifaceted phenomenon extending beyond target site mutations. Efflux pumps, integral membrane proteins that actively expel antibiotics from the bacterial cell, play a crucial role in quinolone resistance. Overexpression or increased activity of these pumps, often driven by mutations in regulatory genes or by the presence of efflux pump-modifying genes on mobile genetic elements, effectively reduces intracellular drug concentrations, diminishing the efficacy of quinolones. Furthermore, the impermeability of the outer membrane in Gram-negative bacteria serves as a significant barrier to quinolone entry, contributing to resistance. Mutations affecting porin proteins, which form channels in the outer membrane, further restrict antibiotic penetration. The acquisition of resistance genes via horizontal gene transfer, particularly through plasmids and transposons, adds another layer of complexity. These mobile genetic elements can carry genes encoding enzymes that modify or inactivate quinolones, effectively neutralizing their antibacterial activity. The dissemination of such resistance genes across diverse bacterial species contributes to the widespread emergence and persistence of quinolone resistance. Understanding the complex interplay between target site mutations, efflux pump activity, membrane permeability, and horizontal gene transfer is crucial for developing effective strategies to combat quinolone resistance. These strategies include developing new quinolone derivatives that circumvent resistance mechanisms, optimizing antibiotic stewardship programs to minimize the selective pressure for resistance, and exploring alternative therapeutic approaches such as combination therapies and novel antimicrobial agents. Ultimately, a multi-pronged approach involving surveillance, prevention, and development of new treatment options is essential to mitigate the escalating threat posed by quinolone resistance.